☆ 4.1 Article

A Single Dose of SARS-CoV-2 Vaccine Primes a Strong Humoral Immune Response in COVID-19-Recovered Patients

VIRAL IMMUNOLOGY (2022)

Related references

Note: Only part of the references are listed.

Editorial Material Geriatrics & Gerontology

Efficacy and safety of COVID-19 vaccines in older people

Roy L. Soiza et al.

Summary: The safety and efficacy of COVID-19 vaccines in older people are crucial for their success, but there is currently a lack of data. While some Phase III trials have made efforts to recruit older people, those with co-morbidities and frailty have still been largely excluded. Older people, their carers, and healthcare professionals will need to make decisions on vaccination acceptance based on limited evidence.

AGE AND AGEING (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Saman Saadat et al.

Summary: This study compared the titers of binding and neutralizing antibodies in healthcare workers previously infected with SARS-CoV-2 after receiving a single dose of mRNA coronavirus vaccine.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Charlotte Manisty et al.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Maria Prendecki et al.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Nicholas G. Davies et al.

Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.

SCIENCE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Joseph E. Ebinger et al.

Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Leonidas Stamatatos et al.

Summary: The study found that vaccination of both previously infected individuals and those who were not infected resulted in increased neutralizing antibody titers, with previously infected individuals showing a greater boost in neutralizing titers. Vaccination of naive individuals also elicited cross-neutralizing responses, but at lower titers.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Catherine J. Reynolds et al.

Summary: Vaccination with a single dose of BNT162b2 after prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants. In contrast, individuals without prior infection showed reduced immunity against variants after receiving a single vaccine dose.

SCIENCE (2021)

Add to Collection

Article Biology

Prolonged humoral and cellular immunity in COVID-19-recovered patients

May A. Alsayb et al.

Summary: The study explored the adaptive immune response against SARS-CoV-2 in recovered COVID-19 patients, finding significantly increased levels of CD4' T cells in those with mild and moderate symptoms. Anti-S IgG antibody production against SARS-CoV-2 spike protein was observed in all recovered patients regardless of clinical presentation, with detectable levels up to 90 days post-infection. Further analysis is needed to understand the relationship between different clinical presentations and lymphocyte activation and function.

SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2021)

Add to Collection

Review Biology

Humoral immune responses in hospitalized COVID-19 patients

Waleed H. Mahallawi

Summary: The study investigated the antibody responses to the SARS-CoV-2 spike protein in hospitalized COVID-19 patients in Saudi Arabia. Severe patients showed significantly higher levels of IgG and IgM antibodies compared to non-severe patients, with males showing higher positivity rates than females. These findings provide insights into the humoral immune responses in COVID-19 patients with varying disease severity.

SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2021)

Add to Collection

Article Immunology

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals after mRNA vaccination

Rishi R. Goel et al.

Summary: mRNA vaccines exhibit robust serological and cellular priming, with naïve individuals requiring two doses for optimal antibody responses, especially against the B.1.351 variant. Memory B cells specific for spike protein and RBD were efficiently primed by vaccination, while recovered individuals showed significant boosting after the first dose, correlating with preexisting memory B cell levels. Identifying distinct responses based on prior SARS-CoV-2 exposure suggests that recovered subjects may only need one vaccine dose for peak responses, which can inform vaccine distribution strategies in resource-limited settings.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses

F. Javier Ibarrondo et al.

Summary: Studies on two SARS-CoV-2 mRNA vaccines have shown that they provide about 95% protection from symptomatic infection in the short term, but questions remain about the comparison and stability of vaccine-induced antibody levels to natural infection. Antibody levels decline similarly after vaccination and natural infection, indicating potential need for booster shots.

ACS NANO (2021)

Add to Collection

Editorial Material Multidisciplinary Sciences

A long-term perspective on immunity to COVID

Andreas Radbruch et al.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Jackson S. Turner et al.

Summary: The study found that individuals who had recovered from mild SARS-CoV-2 infections showed rapid decline of serum anti-SARS-CoV-2 spike protein antibodies in the first 4 months after infection, followed by a more gradual decrease over the following 7 months but remaining detectable at least 11 months after infection. This suggests that mild infection with SARS-CoV-2 can induce robust antigen-specific, long-lived humoral immune memory in humans.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Zijun Wang et al.

Summary: Despite challenges posed by COVID-19 variants, convalescent individuals receiving mRNA vaccines exhibit robust and long-lasting immune responses against circulating SARS-CoV-2 variants, providing hope for effective control of the pandemic.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Ugur Sahin et al.

Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.

NATURE (2021)

Add to Collection

Editorial Material Multidisciplinary Sciences

Hybrid immunity

Shane Crotty

SCIENCE (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors

Matthew Frieman et al.

EBIOMEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Clinical Characteristics of Coronavirus Disease 2019 in China

W. Guan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Immunology

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China

Chuan Qin et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Review Allergy

Influence of immune aging on vaccine responses

Claire E. Gustafson et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Developing Covid-19 Vaccines at Pandemic Speed

Nicole Lurie et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Immunology

I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People

Anna Julia Pietrobon et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

COVID-19: what has been learned and to be learned about the novel coronavirus disease

Ye Yi et al.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2020)

Add to Collection

Review Immunology

B cell development and receptor diversity during aging

D Allman et al.

CURRENT OPINION IN IMMUNOLOGY (2005)

Add to Collection

Article Immunology

Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome

TS Li et al.

JOURNAL OF INFECTIOUS DISEASES (2004)

Add to Collection

Review Immunology

Age-related changes in lymphocyte development and function

PJ Linton et al.

NATURE IMMUNOLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.